Research

Genectically Engineered Oncolytic Virus

RVLYSIS® is a genetically engineered oncolytic virus from the respiratory syncytial virus (RSV) that has been proven to kill cancer cells. As the infected cancer cells are destroyed by oncolysis, they release new infectious virus particles or virions to help destroy the remaining tumour. “The resultant explosion of the cancer cell activates a cascade of anti-tumor immune responses including interferon release. These payloads act in concert with the primary oncolysis mechanism to eradicate the cancer”.

Respiratory Syncytial Virus

Respiratory Syncytial Virus (RSV) is a common and highly contagious virus that infects the respiratory tract of most children before their second birthday. For most babies and young children, the infection causes nothing more than a cold.

“RSV, a virus that causes respiratory infections in infants and young children, selectively kills cancer cells while leaving healthy cells alone”. – School of Medicine at The University of Texas Health Science Center San Antonio

“The animal results were particularly exciting — mice with prostate tumors were treated with the virus and within a week the tumors were gone. “We kept the mice for four months, and the tumors never came back”.- Santanu Bose, Ph.D University of Texas Health Center San Antonio

RVLYSIS®

RVLYSIS® is a genetically engineered RSV that is safer to use than it’s wild-type virus. The invention is within the scope of oncolytic virotherapy.

Multiple Mechanics Action of RVLYSIS®

HERVLYSIS® kills liver cancer

HERVLYSIS® – Genetically Engineered Oncolytic Virus For Liver Cancer

BRVLYSIS® kills Breast Cancer

BRVLYSIS® – Genetically Engineered Oncolytic Virus For Breast Cancer

PRORVLYSIS® (for prostate cancer) has proven effective in overseas trials.

“The volume of the primary tumor had decreased by more than 50% since the prior exam from 8.0 x 6.7 x 6.6 cm3 to 6.3 x 5.4 x 4.7 cm3. In addition, there was a reduction in size of the bilateral lower pelvis lymphadenopathy.

A large nodal mass within the right lower pelvis has decreased from 6.2 x 4.9 cm to 5.2 x 3.6 cm with less mass effect upon the right lateral urinary bladder. A nodal mass within the left lower pelvis has decreased from 5.2 x 4.1 cm to 3.7 x 2.5 cm. Multiple other lymph nodes have decreased as well.

Furthermore, the multiple bony metastases were less apparent in the post treatment images and have faded in signal since the prior exam and the urinary bladder was no longer distended. There is no evidence for progressive or new disease.

Finally, a PSA Test (prostate-specific antigens) was also performed before and after treatment. The initial PSA reading was 490 ng/mL and 3 months post-treatment PSA reading was only 67 ng/mL, a marked decrease”. – Press Release: August 26, 2013

“In summary, there has been a significant positive therapeutic response when compared to prior exam. There has been significant reduction by more than 50% volume of tumor within the prostate bed. Pelvic lymphadenopathy has also significantly decreased in size and multiple bony metastases are less apparent”.

RICHARD M. GOLDBERG, M.D.
Diplomats, American Board of Radiology